Potential Target Patient Populations

Avastin: Colorectal Cancer (CRC)
2010 potential target population

The potential target population for Avastin in first-line colorectal cancer is ~117,000 drug treated patients (40,000 US/77,000 Top 5 EU); the potential target population in second-line colorectal cancer is ~66,000 chemo treated patients (23,000 US/43,000 Top 5 EU).

NB: EU Avastin eligibility, no cut is made for patients who are contraindicated for Avastin – all drug treated patients are assumed eligible for Avastin.
Avastin: Non-Small Cell Lung Cancer (NSCLC)
2010 potential target population

The potential target population for Avastin in first-line non-small cell lung cancer is ~110,000 non-squamous drug treated patients (49,000 US/61,000 Top 5 EU)


Updated Jan 2010
mNSCLC is defined as stage IIIB/IV NSCLC

Avastin: HER2-negative metastatic Breast Cancer (mBC)
2010 potential target population

The potential target population for Avastin in first-line HER2-negative metastatic breast cancer is ~67,000 chemo-treated patients (20,000 US/47,000 Top 5 EU); in second-line HER2-negative metastatic breast cancer the potential target population is ~46,000 chemo treated patients (22,000 US/24,000 Top 5 EU)

Reviewed Jan 2010
Note: Includes 1L and 2L patient populations only
**Avastin: Glioblastoma Multiforme (GBM)**

*2010 potential target population*

The potential target population for Avastin in first-line GBM is ~13,700 Avastin-eligible, drug treated incident patients (8,100 US/5,600 Top 5 EU).

The U.S. potential target population for Avastin in relapsed GBM is ~3,800 Avastin-eligible, drug treated incident patients.

**Avastin for relapsed GBM is not approved in EU**

---

**Avastin: Renal Cell Carcinoma (RCC)**

*2010 potential target population*

The potential target population for Avastin in first-line metastatic renal cell cancer is ~20,300 drug-treated incident patients (10,000 US/10,300 Top 5 EU).
Avastin: Opportunities in the adjuvant setting
2010 potential eligible target population

2010 Estimates for Drug Treated Incident Adjuvant Patients

- Colorectal: 55,000
- NSCLC: 31,000
- HER2+ Breast: 64,000
- HER2-negative: 156,000

Updated January 2010
Source: Estimates from triangulation of multiple sources
Note: Estimated figures represent Drug-Treated Avastin-Eligible Patients

Avastin: Ovarian Cancer
2010 potential target population

The potential target population for Avastin in first-line ovarian cancer is ~36,000 drug treated incident patients (18,000 US/18,000 Top 5 EU)

The potential target population for Avastin in 2nd-line platinum sensitive ovarian cancer is ~19,000 drug treated incident patients (9,000 US/10,000 Top 5 EU)

Updated January 2010
Source: Estimates from triangulation of multiple sources
Note: Estimated figures represent Drug-Treated Avastin-Eligible Patients
Notes IC: For EU, HER2-negative post-menopausal ER-negative include stage II and III. HER2-negative pre-menopausal ER-negative include stage II and III. HER2-negative pre-menopausal ER+ includes only III as they are seen as high risk patients. HER2-negative post-menopausal ER+ includes III.

** EU/US labels expected to reflect eligibility of ICON7 and GOG-218, respectively

Reviewed January 2010
**BRAF (RG7204): 1st line metastatic Melanoma Cancer**

2010 potential target population

The target population for BRAF (RG7204) in 1L BRAF mutation positive metastatic melanoma is ~7,400 drug treated patients (3,600 US/3,800 Top 5 EU)

Updated February 2010

**GDC-0449: Advanced Basal Cell Carcinoma**

2010 potential target population

The target population for GDC-0449 in advanced and metastatic basal cell carcinoma is ~5,000 patients (3,000 US/2,000 Top 5 EU)

*Basal cell carcinoma is not tracked in most cancer registries, including SEER. Prevalence is estimated from incidence rates reported in literature and primary market research.

Herceptin: HER2+ early Breast Cancer (eBC)
2010 potential target population

The target population for Herceptin in HER2+ early (adjuvant) breast cancer is ~68,000 patients (34,000 US/34,000 Top 5 EU)

Updated January 2010

Herceptin in HER2+ 1L metastatic Gastric Cancer
2015 potential target population

In 2015, the target population for Herceptin in HER2+ metastatic gastric cancer is approximately 10,800 eligible patients (4,300 US/6,500 Top 5 EU)

Note: HER2 Testing and eligible assumptions differ between US and 5 EU.
**Herceptin: HER2+ metastatic Breast Cancer (mBC)**

2010 potential target population

The target US and Top 5 EU population for 1L HER2+ metastatic breast cancer is ~20,000 patients (5,000 de novo and 15,000 adjuvant relapse)

The target US and Top 5 EU population for 2L-4L HER2+ metastatic breast cancer is ~28,000 patients (14,000 US/14,000 Top 5 EU)

---

**MabThera/Rituxan: Follicular non-Hodgkin’s Lymphoma (NHL)**

2010 potential target population


Updated January 2010


Stage IV = newly diagnosed cases of stage IV BC

---

13

14
**MabThera/Rituxan: Diffuse large B-Cell non-Hodgkin’s Lymphoma (DLBCL)**

2010 potential target population

![Diagram showing cases of aggressive NHL (2010)]

Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient case market research Q4 2009; Estimates only; Based on SEER and Mattson Jack TA data; 2010 numbers from GNE Rituxan B-cell Epi Model and Rituxan forecast model

**MabThera/Rituxan: Chronic Lymphocytic Leukemia (CLL)**

2010 Potential Target Population

![Diagram showing cases of CLL (2010)]

Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient case market research Q4 2009; Estimates only; Based on SEER and Mattson Jack TA data; 2010 numbers from GNE Rituxan B-cell Epi Model and Rituxan forecast model
**Tarceva: Non-Small Cell Lung Cancer (mNSCLC)**

*2010 potential target population*

Revised January 2010

*Total metastatic NSCLC newly diagnosed or newly progressed drug treated patients*


**2010 Estimates For Number of Newly Diagnosed or Progressed NSCLC Patients (Thousands)**

- **EGFR Mutation Positive ~ 9%**
- **EGFR Mutation Negative ~ 91%**

**Tarceva: Metastatic Pancreatic Cancer**

*2010 potential target population*

Revised February 2010

*Advanced* = Stage IIIb/IV in US and Stage IV in EU


The potential target population for Tarceva in first-line metastatic pancreatic cancer is ~60,000 newly diagnosed and drug treated patients (25,000 US/35,000 Top 5 EU).
Xeloda: Adjuvant Colorectal Cancer
2010 potential target population

The target population for Xeloda in adjuvant colorectal cancer is ~146,000 eligible drug-treated incident patients (71,000 US/75,000 Top 5 EU).

Xeloda: Metastatic Colorectal Cancer (mCRC)
2010 potential target population

The target population for Xeloda in mCRC is ~219,000 eligible drug treated incident patients (75,000 US/144,000 Top 5 EU). Of the drug treated population, the target population in first-line and second-line mCRC is ~118,000 and ~66,000 patients, respectively.
Xeloda: Adjuvant Breast Cancer (eBC)
2010 potential target population

The target population for Xeloda in adjuvant breast cancer is ~332,000 eligible drug treated incident patients (210,000 US/122,000 Top 5 EU)

Updated January 2010
*Drug treated patients = all patients who begin a treatment in a new line of therapy
For the US Adjuvant HER2+ patients are drug treated while metastatic HER2- patients are chemo treated.

Xeloda: Metastatic Breast Cancer (mBC)
2010 potential target population

The target population for Xeloda in metastatic breast cancer in 2010 is ~189,000 eligible drug treated incident patients (96,000 US/93,000 Top 5 EU)

Updated January 2010
*Drug treated patients = all patients who begin a treatment in a new line of therapy
Adjuvant HER2+ patients are drug treated while metastatic HER2- patients are chemo treated.
Xeloda: 1st line metastatic Gastric Cancer
2010 potential target population

The potential target population for Xeloda in metastatic gastric cancer is ~54,000 eligible drug treated incident patients (20,000 US/34,000 Top 5 EU)

Schizophrenia
2010 potential target population

The target population of diagnosed Schizophrenic patients with negative symptoms is ~1.4 million patients (755,000 US/712,000 EU)
**Alzheimer’s disease**

*2010 potential target population*

The potential targeted population for mild and moderate Alzheimer’s patients is ~2 million patients (820,000 US/1.2 million EU)

---

**Major depressive disorder**

*2010 potential target population*

The potential target population for major depressive disorder is ~20 million patients (11 million US/9 million EU)
2nd generation anti-CD20: Relapsing Remitting Multiple Sclerosis (RRMS)
2010 potential target population

Potential target population for 2nd generation anti-CD20 for relapsing remitting multiple sclerosis (RRMS) is ~318,000 patients (173,000 US/145,000 EU)

2nd generation anti-CD20: Primary Progressive Multiple Sclerosis (PPMS)
2010 potential target population

Potential target population for 2nd generation anti-CD20 for primary progressive multiple sclerosis (PPMS) is ~46,000 patients (25,000 US/21,000 EU)
Rituxan and Actemra: TNF-IR Rheumatoid Arthritis
2010 potential target population

Our global target population for Rituxan and Actemra in rheumatoid arthritis is ~290k patients who have an inadequate response to TNF antagonist therapies (i.e., 2nd and 3rd line biologic treated patients) 

(227,000 US/63,000 EU)


Hepatitis C Epidemiology - Over 170 million individuals are chronically infected with Hepatitis C

Prevalence of Hepatitis C in Major Markets in 2010 (thousand) 1

1 Prevalence is defined as individuals positive for HCV RNA. Prevalence is based on WHO population estimates and published literature

2 China model represents the Urban population only
Hepatitis B Epidemiology – Over 400 million individuals are chronically infected with Hepatitis B

Prevalence of Hepatitis B in Major Markets in 2010 (million) 1

1 Prevalence is defined as individuals positive for HBsAg. Prevalence is based on WHO population estimates and published literature
Source: Image adapted from Fung and Lok Hepatol 2004 and Liaw and Chu. Lancet 2009

Over 1 m patients are diagnosed with high grade cervical intraepithelial neoplasia in major markets

Diagnosed Incidence 1 of Cervical Intraepithelial Neoplasia (CIN) Grades II or III in Major Markets in 2010 (000)

1. Represents patients accessible to treatment. Overall incidence population expected to be higher, especially in developing markets
2. Includes UK, France, Germany, Spain, Italy and Eastern Europe
3. Includes S. Africa and Morocco
Source: Roche Epidemiology based on various published literature
**Dalcetrapib**

*Potential target population classified by CV risk*

![Graph showing potential target population classified by CV risk.](image)

*2009 Projected Figures
Source: Roche epidemiology prevalence projection based on National Center for Health Statistics NHANES data

---

**Aleglitazar**

*Target population growing rapidly*

![Graph showing target population growing rapidly.](image)

Objective: following a recent Acute Coronary Syndrome in adults with concomitant T2D, reduction of:
- CV mortality
- non-fatal MI
- stroke